Assessment of BRAF and KIT mutations in Japanese melanoma patients

Journal of Dermatological Science

Volumn 66, Issue 3, 2012, Pages 240-242

  Ashida, Atsuko ^a   Uhara, Hisashi ^a   Kiniwa, Yukiko ^a   Oguchi, Misae ^a   Murata, Hiroshi ^a   Goto, Yasufumi ^a   Uchiyama, Aya ^a   Ogawa, Eisaku ^a   Hayashi, Koichi ^a   Koga, Hiroshi ^a   Okuyama, Ryuhei ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BRAF; KIT; Melanoma; Molecular targeted therapy; Mutations

Indexed keywords

B RAF KINASE; GENOMIC DNA; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; BRAF GENE; CLINICAL FEATURE; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; HUMAN TISSUE; JAPANESE; LETTER; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE C KIT; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; EXONS; GENOTYPE; HUMANS; JAPAN; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 84861344270     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.03.005     Document Type: Letter

References (10)

1. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
2. Carvajal R.D., Antonescu C.R., Wolchok J.D., Chapman P.B., Roman R.A., Teitcher J., et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305:2327-2334.
3. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
4. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
5. Kong Y., Si L., Zhu Y., Xu X., Corless C.L., Flaherty K.T., et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011, 17:1684-1691.
6. Si L., Kong Y., Xu X., Flaherty K.T., Sheng X., Cui C., et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012, 48:94-100.
7. Ashida A., Takata M., Murata H., Kido K., Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009, 124:862-868.
8. Rubinstein J.C., Sznol M., Pavlick A.C., Ariyan S., Cheng E., Bacchiocchi A., et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010, 8:67.
9. Lin J., Goto Y., Murata H., Sakaizawa K., Uchiyama A., Saida T., et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 2011, 104:464-468.
10. Sakaizawa K., Goto Y., Kiniwa Y., Uchiyama A., Harada K., Shimada S., et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 2012, 106:939-946.